GSK · Pharma and healthcare · one day
GSK (GSK): news on Saturday 21 November 2026
News from the 24 hours to Saturday morning, 21 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly positive, led by FDA approval of a lung cancer treatment and an early approval for Nelkarmi. Further support came from a Japanese orphan designation, encouraging tuberculosis trial data, a new Singapore facility and a modest share price rise.
What drove it
- FDA approvals
- pipeline progress
- share price gains
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 15 Nov | +7.0 | 6 |
| Mon 16 Nov | +2.5 | 4 |
| Tue 17 Nov | +5.7 | 8 |
| Wed 18 Nov | +7.5 | 36 |
| Thu 19 Nov | 0.0 | 1 |
| Fri 20 Nov | +6.3 | 22 |
| Sat 21 Nov | +7.2 | 11 |
6 stories · 11 headlines · strongest first
Pharma and healthcare on 21 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK news coverage +9.42 headlines today · 28 in all, since 18 November · Coverage of FDA approval of GSK's lung cancer treatment. | ||
| +10.0 | Regulatory clearance for a lung cancer therapy opens a new market. | |
| +9.2 | Early regulatory approval of a new product is a positive. | |
| BioVersys-GSK antibiotic combination shows promise in TB trial +6.42 headlines today · A GSK-partnered antibiotic combo showed promise in a Phase II TB trial. | ||
| +7.0 | Shares helped by positive tuberculosis drug trial news. | |
| +5.8 | Partnered tuberculosis antibiotic combination showed encouraging mid-stage trial data. | |
| GSK share outlook and market commentary +0.62 headlines today · 13 in all, since 17 November · Pieces discuss a 1.6% share rise and the new FTSE session. | ||
| +6.7 | Share price rose, with coverage looking at the cause. | |
| +0.8 | Market session preview with little substance on the company. | |
| Japan gives velzatinib orphan designation for GIST +5.92 headlines today · 10 in all, since 20 November · Japanese authorities designated GSK's velzatinib an orphan drug in GIST. | ||
| +6.7 | Japanese designation for a rare-tumour drug, with recent share gains. | |
| +6.3 | Special regulatory designation in Japan supports a pipeline drug. | |
| GSK transfers treasury shares to back awards +0.22 headlines today · GSK transferred treasury shares to JPMorgan for ADRs to back award plans. | ||
| +0.3 | Routine treasury share transfer to fund employee award plans. | |
| 0.0 | Administrative filing about shares backing staff incentive plans. | |
| GSK launches high-potency production site in Singapore +5.81 headline today · GSK opened a high-potency drug facility in Singapore. | ||
| +5.8 | New manufacturing site expands capacity for cancer medicines. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.